Eintrag weiter verarbeiten
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
Gespeichert in:
| Zeitschriftentitel: | Journal of Pineal Research |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Journal of Pineal Research, 21, 1996, 4, S. 239-242 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. |
|---|---|
| author |
Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. |
| spellingShingle |
Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. Journal of Pineal Research Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma Endocrinology |
| author_sort |
lissoni, r |
| spelling |
Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. 0742-3098 1600-079X Wiley Endocrinology http://dx.doi.org/10.1111/j.1600-079x.1996.tb00292.x <jats:p><jats:bold>Abstract: </jats:bold> Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma. Our previous clinical studies demonstrated that melatonin may induce stabilization of the disease in untreatable metastatic solid tumor patients, and these results have been confirmed by others, at least in patients with metastatic melanoma. On the contrary, at present there are no data related to the possible efficacy of melatonin as an adjuvant endocrine therapy. This study was performed to investigate the impact of melatonin therapy on the disease‐free survival (DFS) in melanoma patients surgically treated for regional node recurrence. The study included 30 node‐relapsed melanoma patients, who were randomized to receive no treatment or adjuvant therapy of melatonin (20 mg/day orally in the evening) every day until disease progression. After a median follow‐up of 31 months, the percent of DFS was significantly higher in melatonin‐treated individuals than in controls. The DFS curve was also significantly longer in melatonin group than in controls. No melatonin‐related toxicity was observed. This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients.</jats:p> Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma Journal of Pineal Research |
| doi_str_mv |
10.1111/j.1600-079x.1996.tb00292.x |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE2MDAtMDc5eC4xOTk2LnRiMDAyOTIueA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE2MDAtMDc5eC4xOTk2LnRiMDAyOTIueA |
| institution |
DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
Wiley, 1996 |
| imprint_str_mv |
Wiley, 1996 |
| issn |
0742-3098 1600-079X |
| issn_str_mv |
0742-3098 1600-079X |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
lissoni1996adjuvanttherapywiththepinealhormonemelatonininpatientswithlymphnoderelapseduetomalignantmelanoma |
| publishDateSort |
1996 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Pineal Research |
| source_id |
49 |
| title |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_unstemmed |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_full |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_fullStr |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_full_unstemmed |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_short |
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_sort |
adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| topic |
Endocrinology |
| url |
http://dx.doi.org/10.1111/j.1600-079x.1996.tb00292.x |
| publishDate |
1996 |
| physical |
239-242 |
| description |
<jats:p><jats:bold>Abstract: </jats:bold> Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma. Our previous clinical studies demonstrated that melatonin may induce stabilization of the disease in untreatable metastatic solid tumor patients, and these results have been confirmed by others, at least in patients with metastatic melanoma. On the contrary, at present there are no data related to the possible efficacy of melatonin as an adjuvant endocrine therapy. This study was performed to investigate the impact of melatonin therapy on the disease‐free survival (DFS) in melanoma patients surgically treated for regional node recurrence. The study included 30 node‐relapsed melanoma patients, who were randomized to receive no treatment or adjuvant therapy of melatonin (20 mg/day orally in the evening) every day until disease progression. After a median follow‐up of 31 months, the percent of DFS was significantly higher in melatonin‐treated individuals than in controls. The DFS curve was also significantly longer in melatonin group than in controls. No melatonin‐related toxicity was observed. This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients.</jats:p> |
| container_issue |
4 |
| container_start_page |
239 |
| container_title |
Journal of Pineal Research |
| container_volume |
21 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337276424945664 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:13:46.725Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Adjuvant+therapy+with+the+pineal+hormone+melatonin+in+patients+with+lymph+node+relapse+due+to+malignant+melanoma&rft.date=1996-11-01&genre=article&issn=1600-079X&volume=21&issue=4&spage=239&epage=242&pages=239-242&jtitle=Journal+of+Pineal+Research&atitle=Adjuvant+therapy+with+the+pineal+hormone+melatonin+in+patients+with+lymph+node+relapse+due+to+malignant+melanoma&aulast=Meregalli&aufirst=S.&rft_id=info%3Adoi%2F10.1111%2Fj.1600-079x.1996.tb00292.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337276424945664 |
| author | Lissoni, R, Brivio, O., Brivio, F., Barni, S., Tancini, G., Crippa, D., Meregalli, S. |
| author_facet | Lissoni, R, Brivio, O., Brivio, F., Barni, S., Tancini, G., Crippa, D., Meregalli, S., Lissoni, R, Brivio, O., Brivio, F., Barni, S., Tancini, G., Crippa, D., Meregalli, S. |
| author_sort | lissoni, r |
| container_issue | 4 |
| container_start_page | 239 |
| container_title | Journal of Pineal Research |
| container_volume | 21 |
| description | <jats:p><jats:bold>Abstract: </jats:bold> Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma. Our previous clinical studies demonstrated that melatonin may induce stabilization of the disease in untreatable metastatic solid tumor patients, and these results have been confirmed by others, at least in patients with metastatic melanoma. On the contrary, at present there are no data related to the possible efficacy of melatonin as an adjuvant endocrine therapy. This study was performed to investigate the impact of melatonin therapy on the disease‐free survival (DFS) in melanoma patients surgically treated for regional node recurrence. The study included 30 node‐relapsed melanoma patients, who were randomized to receive no treatment or adjuvant therapy of melatonin (20 mg/day orally in the evening) every day until disease progression. After a median follow‐up of 31 months, the percent of DFS was significantly higher in melatonin‐treated individuals than in controls. The DFS curve was also significantly longer in melatonin group than in controls. No melatonin‐related toxicity was observed. This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients.</jats:p> |
| doi_str_mv | 10.1111/j.1600-079x.1996.tb00292.x |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE2MDAtMDc5eC4xOTk2LnRiMDAyOTIueA |
| imprint | Wiley, 1996 |
| imprint_str_mv | Wiley, 1996 |
| institution | DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0742-3098, 1600-079X |
| issn_str_mv | 0742-3098, 1600-079X |
| language | English |
| last_indexed | 2024-03-01T15:13:46.725Z |
| match_str | lissoni1996adjuvanttherapywiththepinealhormonemelatonininpatientswithlymphnoderelapseduetomalignantmelanoma |
| mega_collection | Wiley (CrossRef) |
| physical | 239-242 |
| publishDate | 1996 |
| publishDateSort | 1996 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Pineal Research |
| source_id | 49 |
| spelling | Lissoni, R Brivio, O. Brivio, F. Barni, S. Tancini, G. Crippa, D. Meregalli, S. 0742-3098 1600-079X Wiley Endocrinology http://dx.doi.org/10.1111/j.1600-079x.1996.tb00292.x <jats:p><jats:bold>Abstract: </jats:bold> Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma. Our previous clinical studies demonstrated that melatonin may induce stabilization of the disease in untreatable metastatic solid tumor patients, and these results have been confirmed by others, at least in patients with metastatic melanoma. On the contrary, at present there are no data related to the possible efficacy of melatonin as an adjuvant endocrine therapy. This study was performed to investigate the impact of melatonin therapy on the disease‐free survival (DFS) in melanoma patients surgically treated for regional node recurrence. The study included 30 node‐relapsed melanoma patients, who were randomized to receive no treatment or adjuvant therapy of melatonin (20 mg/day orally in the evening) every day until disease progression. After a median follow‐up of 31 months, the percent of DFS was significantly higher in melatonin‐treated individuals than in controls. The DFS curve was also significantly longer in melatonin group than in controls. No melatonin‐related toxicity was observed. This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients.</jats:p> Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma Journal of Pineal Research |
| spellingShingle | Lissoni, R, Brivio, O., Brivio, F., Barni, S., Tancini, G., Crippa, D., Meregalli, S., Journal of Pineal Research, Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma, Endocrinology |
| title | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_full | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_fullStr | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_full_unstemmed | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_short | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_sort | adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| title_unstemmed | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma |
| topic | Endocrinology |
| url | http://dx.doi.org/10.1111/j.1600-079x.1996.tb00292.x |